BioMedNewsBreaks – HealthLynked Corp. (HLYK) Launches Innovative, AI-Powered Chat Function

HealthLynked (OTCQB: HLYK), a leading innovator in healthcare technology, today unveiled its new AI-powered chat function designed to assist patients in finding healthcare providers across the country. The new AI chat bot will significantly enhance the effectiveness of the HealthLynked Concierge Team, reducing wait times and offering 24/7 service to users. The advanced feature will provide instant answers to customer questions as well as assist in locating healthcare providers by name, specialty or location. “Our new AI chat function is a testament to our commitment to leveraging cutting-edge technology to improve healthcare accessibility,” said Dr. Michael Dent, CEO of HealthLynked. “By integrating AI into our platform, we can provide more efficient and timely support to our users, ensuring they receive the care they need without unnecessary delays.”

To view the full press release, visit https://ibn.fm/Jouf1

About HealthLynked Corp.

HealthLynked is dedicated to improving global community health. Its mission unfolds in two pivotal goals: First, to transform healthcare into a system marked by enhanced efficiency and improved care for all, leveraging cutting-edge technology and connectivity. Second, to forge a patient-centric network that not only places patients at the heart of their healthcare journey but also mobilizes their participation to accelerate medical discoveries and the development of cures for diseases that impact humanity. This pioneering model empowers individuals with unparalleled access to and control over their medical information, fostering a collaborative environment where every patient contribution can spearhead breakthroughs in health and wellness. Through these concerted efforts, HealthLynked aims to secure a healthier future for generations to come. For more information about the company, visit www.HealthLynked.com.

NOTE TO INVESTORS: The latest news and updates relating to HealthLynked are available in the company’s newsroom at https://IBN.fm/HLYK

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Advances Orphan Drug Strategy With HyBryte In Rare Skin Cancer

Soligenix (NASDAQ: SNGX) is advancing a differentiated approach to orphan drug development, emphasizing a de-risked model focused…

2 hours ago

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting 

Soligenix (NASDAQ: SNGX) announced that new supportive trial data for HyBryte(TM) in the treatment of cutaneous T-cell lymphoma…

6 hours ago

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Subsidiary Sapu Nano To Present Everolimus Toxicology Data At SOT 2026

Oncotelic Therapeutics (OTCQB: OTLC) announced that its subsidiary Sapu Nano will present new data on…

7 hours ago

BioMedNewsBreaks — Co-Diagnostics, Inc. (NASDAQ: CODX) Expands CoSara Distribution Territory Across South Asia 

Co-Diagnostics (NASDAQ: CODX) announced that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., has signed an agreement to expand…

3 days ago

BioMedNewsBreaks — Black Hawk Acquisition Corporation (Nasdaq: BKHA) SPAC Target Vesicor Therapeutics Names Michael Tolentino CEO

Black Hawk Acquisition (Nasdaq: BKHA, BKHAU, BKHAR) announced that its proposed de-SPAC acquisition target, Vesicor Therapeutics Inc., has…

3 days ago

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Highlights HyBryte Clinical Data In Peer-Reviewed Journal Publication

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced that a comprehensive summary of clinical…

4 days ago